Serodus ASA Share Price

Stocks

03/01/17	Serodus : Primary endpoint reached by SER150 Phase 2a study in Diabetic Nephropathy.	PU
08/12/16	Serodus : Q&A delisting from Oslo Axess	PU
23/11/16	Serodus : Extraordinary general meeting held	PU
23/11/16	Serodus : Viggo Harboe Holding 2006 ApS announces results of voluntary offer	PU
02/11/16	Serodus : Viggo Harboe Holding 2006 Aps Launces voluntary offer for outstanding shares in Serodus ASA – Acceptance period starting 31 October 2016	PU

1 day

-5.56%

Manager	Title	Age	Since
Arnstein Gunnestad Endresen CEO	Chief Executive Officer	73	31/12/2022
Henrik Mordhorst DFI	Director of Finance/CFO	-	30/09/2019
Daniel Capion PRN	Corporate Officer/Principal	-	31/12/2020

Director	Title	Age	Since
Søren Elmann Ingerslev CHM	Chairman	-	31/12/2016
Terri Sebree BRD	Director/Board Member	68	31/03/2014
Viggo Gunnersen Harboe BRD	Director/Board Member	80	31/12/2021

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SERODUS ASA	-5.56%	+7.94%	-	-	0
WUXI APPTEC CO., LTD.	+8.49%	+23.38%	+65.44%	+104.90%	62.92B
ARGENX SE	+1.25%	+2.22%	+31.00%	+70.51%	54.32B
BIONTECH SE	+2.72%	+0.88%	-15.84%	-12.03%	22.91B
INSMED INCORPORATED	-1.09%	+29.18%	+17.83%	+496.18%	28.73B
WUXI BIOLOGICS (CAYMAN) INC.	+10.83%	+21.32%	+45.03%	+2.02%	21.65B
GENMAB A/S	+6.50%	+8.41%	+45.17%	-21.02%	17.76B
PHARMAESSENTIA CORPORATION	-3.88%	+20.98%	+201.07%	+350.94%	16.47B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+6.20%	+12.16%	+28.51%	+629.05%	15.48B
EXELIXIS, INC.	+3.58%	-3.39%	+43.38%	+166.75%	13.12B
Average	+2.90%	+7.42%	+51.29%	+198.59%	28.15B
Weighted average by Cap.	+4.19%	+9.95%	+47.56%	+164.93%

Employees

Sector